- Conditions
- Placebo Effect, Mindfulness, Pain, Transcranial Direct Current Stimulation (tDCS)
- Interventions
- tDCS stimulation (sham), tDCS stimulation (real), Mindful state induction, No minfulness induction
- Behavioral
- Lead sponsor
- Trustees of Dartmouth College
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Hanover, New Hampshire
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 2,822
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- REGN1033(SAR391786), Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Honolulu, Hawaii • Evansville, Indiana
- Conditions
- Covid19
- Interventions
- Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo, Part B: Upamostat 200 or 400 mg
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 11
- States / cities
- Cutler Bay, Florida • Hialeah, Florida • Miami, Florida + 7 more
- Conditions
- Healthy Participants
- Interventions
- ALG-000184, Placebo, [14C]ALG-000184, [13C7,15N1]ALG-001075
- Drug · Radiation
- Lead sponsor
- Aligos Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Healthy
- Interventions
- sisunatovir, placebo, moxifloxacin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
- Drug · Other · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 24
- States / cities
- Costa Mesa, California • La Jolla, California • Orange, California + 19 more
- Conditions
- Osteoarthritis
- Interventions
- Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 8
- States / cities
- Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- AD109 dose1- A, AD109 dose2- B, Placebo- C
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- San Diego, California • Atlanta, Georgia • Philadelphia, Pennsylvania
- Conditions
- Influenza
- Interventions
- CAIV-T
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000
- U.S. locations
- 1
- States / cities
- Stamford, Connecticut
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Domvanalimab, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 791 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more
- Conditions
- Diabetic Foot Ulcer
- Interventions
- gentamicin-collagen sponge, placebo collagen sponge
- Drug
- Lead sponsor
- Innocoll
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Pasadena, Maryland
- Conditions
- Solid Tumours
- Interventions
- Selumetinib, Moxifloxacin, selumetinib placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Interventions
- parsaclisib, ruxolitinib, placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 36
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 4
- States / cities
- Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
- Conditions
- Diabetes
- Interventions
- Placebo, AGI-1067
- Drug
- Lead sponsor
- AtheroGenics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Stockbridge, Georgia • San Antonio, Texas
- Conditions
- Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer
- Interventions
- Bevacizumab, Carboplatin, Paclitaxel, Placebo, Trastuzumab
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 373
- States / cities
- Jonesboro, Arkansas • Castro Valley, California • Emeryville, California + 236 more
- Conditions
- Sinusitis, Respiratory Tract Infections
- Interventions
- Amoxicillin-clavulanate, Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Bardstown, Kentucky • Gresham, Oregon • Philadelphia, Pennsylvania + 3 more
- Conditions
- Healthy Volunteers
- Interventions
- MAS825, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Overland Park, Kansas
- Conditions
- COPD, Respiratory Disease, Lower Respiratory Disease, Pulmonary Disease, Healthy
- Interventions
- Vapendavir
- Drug
- Lead sponsor
- Altesa Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Hepatitis B
- Interventions
- Bepirovirsen, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Alopecia Areata
- Interventions
- bempikibart (ADX-914)
- Drug
- Lead sponsor
- Q32 Bio Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 28
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more
- Conditions
- SCN2A Encephalopathy, SCN8A Encephalopathy
- Interventions
- PRAX-562
- Drug
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more